AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class causing autophagy molecules by the overexpression of Tribbles pseudokinase 3 (TRIB3) to treat multiple aggressive cancers. Overexpression of TRIB3 to inhibit the PI3K/Akt/mTOR pathway represents a novel approach, offering an opportunity to create important new therapeutic options for cancer patients.
